This edition of the Genetic Technology TOE depicts trends across anticancer and antimicrobial therapies. Selected antitumoral and antimicrobial platform technologies including radio-conjugate platforms and checkpoint inhibitor immunotherapies for enhancing targeted therapies, as well as, synthetic macromolecules for addressing multi-drug bacterial resistance have been profiled. The corresponding clinical trials scenario is depicted for Actinium-225-labeled humanized anti-CD33 monoclonal antibody HuM195 and UCART19.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
Innovations in Anti-Tumor and Antimicrobial Platforms
- Novel Radio-conjugate Platform for Enhancing Targeted Therapies
- Accelerating Cancer Immunotherapy Development
- Novel Checkpoint Inhibitor Therapy
- Leveraging Synthetic Macromolecules to Fight Multi-drug Resistant Bacteria
Clinical Trial Analysis and Industry Interactions
- Clinical Trial Analysis for Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195 and UCART19
- Key Contacts
